TFFP | TFF Pharmaceuticals, Inc. | [NASD]
Index- P/E- EPS (ttm)-1.07 Insider Own0.60% Shs Outstand36.19M Perf Week-19.00%
Market Cap19.91M Forward P/E- EPS next Y-0.60 Insider Trans100.91% Shs Float19.03M Perf Month-10.33%
Income-30.40M PEG- EPS next Q-0.19 Inst Own16.70% Short Float / Ratio0.72% / 0.97 Perf Quarter-33.03%
Sales0.50M P/S39.82 EPS this Y15.30% Inst Trans0.67% Short Interest0.14M Perf Half Y-62.80%
Book/sh0.46 P/B1.09 EPS next Y10.40% ROA-134.60% Target Price7.75 Perf Year-91.31%
Cash/sh0.31 P/C1.63 EPS next 5Y- ROE-149.60% 52W Range0.48 - 6.73 Perf YTD-52.17%
Dividend- P/FCF- EPS past 5Y- ROI-138.90% 52W High-92.54% Beta1.17
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin- 52W Low4.63% ATR0.07
Employees15 Current Ratio8.90 Sales Q/Q0.00% Oper. Margin- RSI (14)32.54 Volatility14.15% 12.26%
OptionableYes Debt/Eq0.00 EPS Q/Q41.00% Profit Margin- Rel Volume0.51 Prev Close0.55
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume140.96K Price0.50
Recom2.00 SMA20-23.72% SMA50-24.16% SMA200-74.31% Volume72,238 Change-8.69%
Date Action Analyst Rating Change Price Target Change
May-19-22Resumed H.C. Wainwright Buy $22
Feb-08-21Initiated H.C. Wainwright Buy $31
Dec-07-20Initiated B. Riley Securities Buy $36
Aug-17-20Reiterated Maxim Group Buy $12 → $18
Jul-08-20Initiated Maxim Group Buy $12
May-23-23 04:05PM
May-11-23 04:05PM
May-09-23 07:15AM
May-04-23 08:00AM
May-01-23 07:00AM
08:58AM Loading…
Apr-08-23 08:58AM
Mar-07-23 04:15PM
Mar-06-23 04:05PM
Feb-23-23 01:01PM
Feb-08-23 04:05PM
Jan-09-23 08:00AM
Dec-05-22 06:30AM
Nov-29-22 04:01PM
Nov-21-22 01:40PM
Nov-18-22 08:00AM
04:01PM Loading…
Nov-17-22 04:01PM
Nov-14-22 04:01PM
Nov-07-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 12:47PM
Nov-01-22 04:07PM
Oct-18-22 10:23AM
Oct-11-22 08:00AM
Sep-26-22 08:00AM
Sep-22-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-12-22 11:30AM
04:05PM Loading…
Aug-11-22 04:05PM
Aug-02-22 04:05PM
Jul-14-22 08:00AM
Jun-24-22 03:44PM
Jun-09-22 08:00AM
Jun-01-22 08:00AM
May-31-22 09:55AM
May-20-22 09:32AM
May-11-22 05:15PM
May-10-22 03:34PM
May-02-22 08:00AM
Apr-29-22 07:30AM
Apr-28-22 08:04AM
Apr-19-22 08:00AM
Apr-05-22 09:09PM
Mar-25-22 12:00AM
Mar-24-22 05:45PM
Mar-17-22 11:07AM
Mar-11-22 07:05AM
Mar-09-22 04:05PM
Mar-07-22 10:16AM
Mar-01-22 08:00AM
Feb-24-22 02:29PM
Jan-27-22 08:00AM
Jan-12-22 09:34AM
Dec-21-21 08:00AM
Dec-06-21 08:00AM
Nov-16-21 01:00AM
Nov-15-21 05:25PM
Nov-08-21 08:03AM
Nov-05-21 04:05PM
Oct-28-21 12:03PM
Oct-14-21 03:05PM
Sep-23-21 11:07AM
Sep-08-21 04:05PM
Aug-16-21 08:30AM
Aug-13-21 02:31AM
Aug-12-21 04:01PM
Aug-05-21 08:30AM
Aug-04-21 09:00AM
Jul-29-21 08:00AM
Jul-28-21 03:45PM
Jul-14-21 03:23PM
Jul-13-21 08:00AM
Jul-08-21 09:07AM
Jul-06-21 07:32AM
Jun-28-21 09:05AM
Jun-22-21 08:00AM
Jun-07-21 08:00AM
May-25-21 05:09PM
May-14-21 01:30AM
May-13-21 04:00PM
May-07-21 09:47AM
May-04-21 08:32AM
Apr-13-21 09:00AM
Mar-26-21 08:30AM
Mar-19-21 02:21PM
Mar-10-21 04:00PM
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weisman Harlan FPresident and CEOMar 10Buy0.88150,000131,835214,615Mar 13 08:00 AM
Mikhak ZamanehChief Medical OfficerMar 10Buy0.8215,00012,30015,000Mar 13 08:00 AM
ROCAMBOLI STEPHENDirectorMar 10Buy0.8013,00010,43216,000Mar 13 04:22 PM
COLEMAN KIRK ALLENChief Financial OfficerMar 10Buy0.7912,0009,45715,675Mar 13 08:00 AM
Weisman Harlan FPresident and CEODec 15Buy1.0650,00053,00064,615Dec 19 08:00 AM
Fletcher Aaron G.L.DirectorNov 22Buy1.1543,47049,990143,470Nov 23 07:59 AM
THURMAN RANDY HDirectorSep 29Option Exercise2.5040,255100,63840,255Sep 30 05:20 PM
THURMAN RANDY HDirectorSep 29Sale4.2940,255172,6940Sep 30 05:20 PM